AVIR — Atea Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $313.09m
- -$265.01m
- 50
- 45
- 81
- 60
Annual income statement for Atea Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 48.6 | 351 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14.6 | 59.7 | 213 | 131 | 164 |
| Operating Profit | -14.6 | -11 | 138 | -131 | -164 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -14 | -10.9 | 139 | -119 | -135 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14 | -10.9 | 121 | -116 | -136 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14 | -10.9 | 121 | -116 | -136 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14 | -10.9 | 121 | -116 | -136 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.174 | 0.147 | 2.3 | -1.24 | -1.29 |
| Dividends per Share |